ReviewCurrent medicinal chemistry2026
Participation of MDM2 in Pro-Apoptotic and Androgen Receptor- Degrading Potency of Selected Steroid and Terpenoid Derivatives.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to highlight anti-proliferative, pro-apoptotic, and androgen receptor-degrading activity of selected steroid and terpenoid derivatives in cancer cells, primarily in prostate cancer cells. Steroid and terpenoid derivatives (steroid hybrids, comprising androstane or pregnane skeleton associated with nitrogen containing heterocycle, some natural sterols, bile acids, and related semi-synthetic derivatives; oleanane and ursane type pentacyclic triterpenoids; lanostane and dammarane type tetracyclic triterpenoids), were reported earlier to cause the death of cancer cells via apoptosis; some compounds exhibited significant anticancer potency in vivo and may be considered as promising anticancer agents. The presented data indicate that direct interaction of steroid and terpenoid derivatives with the key oncogenic protein MDM2 makes a significant contribution to anti-proliferative, pro-apoptotic, and androgen receptordegrading activity of these compounds. It triggers apoptosis, which leads to cell death. Structural optimization of steroid and terpenoid derivatives can significantly increase their affinity to MDM2 and improve their anti-proliferative, pro-apoptotic, and androgen receptor-degrading activity.
Indexed as
Identifiers
40765082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.